<p>Kura Oncology（纳斯达克代码：KURA - 获取免费报告）在 Zacks Research 发布的一份报告中被升级，从 “强烈卖出” 评级提升至 “持有” 评级，报告于周三发布，Zacks.com 报道。</p>
<ul>
<li>Kintara Therapeutics 是隐藏的宝石吗？</li>
</ul>
<p>KURA 还受到其他多份研究报告的关注。Wedbush 在 10 月 20 日的报告中重申了 “跑赢大盘” 评级，并设定了 Kura Oncology 股票的目标价为 36.00 美元。HC Wainwright 在 10 月 20 日的研究报告中重申了 “买入” 评级，并设定了 Kura Oncology 股票的目标价为 40.00 美元。Weiss Ratings 在 10 月 8 日的研究报告中重申了 Kura Oncology 股票的 “卖出（d-）” 评级。Guggenheim 在 9 月 4 日的研究报告中开始覆盖 Kura Oncology，并对该股票设定了 “中性” 评级。最后，JMP Securities 在 10 月 20 日的研究报告中重申了 “市场跑赢大盘” 评级，并设定了 Kura Oncology 股票的目标价为 24.00 美元。十位投资分析师对该股票给予了买入评级，四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Kura Oncology 的平均评级为 “适度买入”，平均目标价为 24.67 美元。</p>
<p>获取 <strong>Kura Oncology</strong> 的提醒：</p>
<p><strong>查看我们关于 Kura Oncology 的最新股票报告</strong></p>
<h2>Kura Oncology 价格表现</h2>
<p>KURA 在周三开盘价为 10.16 美元。该公司的 50 日移动平均价为 9.17 美元，200 日移动平均价为 7.30 美元。该股票的市值为 8.8412 亿美元，市盈率为-4.10，贝塔值为 0.35。公司快速比率为 6.16，流动比率为 5.12，债务与股本比率为 0.02。Kura Oncology 的 52 周低点为 5.41 美元，52 周高点为 19.73 美元。</p>
<p>Kura Oncology（纳斯达克代码：KURA - 获取免费报告）最近于 11 月 4 日发布了其财报。该公司报告季度每股收益为（0.85 美元），低于分析师一致预期的（0.57 美元）0.28 美元。该季度的营业收入为 2075 万美元，而分析师预期为 1748 万美元。Kura Oncology 的股本回报率为-65.42%，净利润率为-208.48%。整体来看，卖方分析师预计 Kura Oncology 在当前年度将发布-2.44 的每股收益。</p>
<h2>Kura Oncology 的内部买卖</h2>
<p>在相关消息中，内部人士 Brian T. Powl 于 9 月 29 日星期一出售了 8891 股公司的股票。该股票以平均价格 8.94 美元出售，总交易额为 79485.54 美元。交易后，该内部人士直接持有公司股票 99676 股，价值 891103.44 美元。这代表其持股比例下降了 8.19%。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，内部人士 Teresa Brophy Bair 于 9 月 29 日星期一出售了 8805 股股票。该股票以平均价格 8.94 美元出售，总价值为 78716.70 美元。交易完成后，该内部人士持有公司股票 148043 股，价值约 1323504.42 美元。此交易代表其持股比例下降了 5.61%。该交易的 SEC 文件提供了更多信息。在过去 90 天内，内部人士出售了 78058 股公司股票，价值为 697839 美元。公司内部人士持有公司股票的 6.40%。</p>
<h2>对 Kura Oncology 的对冲基金看法</h2>
<p>几家对冲基金最近调整了对该股票的持有。Cerity Partners LLC 在第一季度收购了 Kura Oncology 的新股份，价值约 210,000 美元。CWM LLC 在第一季度将其在 Kura Oncology 的持股增加了 892.8%。CWM LLC 现在拥有 28353 股公司股票，价值 187,000 美元，此前在上个季度购买了 25497 股。Jennison Associates LLC 在第一季度将其在 Kura Oncology 的持股增加了 93.8%。Jennison Associates LLC 现在拥有 138532 股公司股票，价值 914,000 美元，此前在上个季度购买了 67035 股。1492 Capital Management LLC 在第一季度将其在 Kura Oncology 的持股增加了 25.4%。1492 Capital Management LLC 现在拥有 429746 股公司股票，价值 2836000 美元，此前在此期间购买了 87148 股。最后，Zurcher Kantonalbank Zurich Cantonalbank 在第一季度将其在 Kura Oncology 的持股增加了 23.1%。Zurcher Kantonalbank Zurich Cantonalbank 现在拥有 32784 股公司股票，价值 216,000 美元，此前在此期间购买了 6154 股。</p>
<h2>Kura Oncology 公司简介</h2>
<p>（获取免费报告）</p>
<p>Kura Oncology, Inc 是一家临床阶段的生物制药公司，开发用于癌症治疗的药物。该公司的产品管线包括针对癌症的小分子候选药物。其主要产品候选药物包括 ziftomenib，一种口服生物可用的小分子抑制剂，针对 menin-KMT2A 相互作用，用于治疗包括急性髓性白血病和急性淋巴细胞白血病在内的基因定义亚型的急性白血病；tipifarnib，一种口服生物可用的法尼基转移酶抑制剂，结合 alpelisib 用于 PIK3CA 依赖的头颈鳞状细胞癌患者；以及 KO-2806，一种法尼基转移酶抑制剂，用于治疗实体瘤。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Kura Oncology 更好</li>
<li>投资旅游股票的好处</li>
<li>CAVA 股票在财报失利后寻找方向</li>
<li>公用事业股票解析 – 如何以及为何投资公用事业</li>
<li>3 只准备爆发的小型 AI 股票（均低于 20 美元）</li>
<li>最佳航空航天股票投资</li>
<li>在下跌 16% 后，分析师关注 Meta Platforms 的大幅反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1VSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1VSQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Kura Oncology 吗？</h2>
<p>在考虑 Kura Oncology 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Kura Oncology 并不在名单上。</p>
<p>虽然 Kura Oncology 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KURA

<p>Zacks Research 将 Kura Oncology (NASDAQ:KURA) 的评级从 “强烈卖出” 上调至 “持有”。其他分析师的意见各异，Wedbush 设定了 36 美元的目标价，而 HC Wainwright 则设定了 40 美元的目标价。KURA 的开盘价为 10.16 美元，市值为 8.8412 亿美元。公司报告每股亏损 0.85 美元，未达到预期，但营收为 2075 万美元，超出预期。内部交易出现显著销售，最近对冲基金增加了在该公司的持股</p>

<p>Kura Oncology (NASDAQ:KURA - Get Free Report) was upgraded by equities researchers at Zacks Research from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report issued on Wednesday,Zacks.com reports.</p>
<div class="lb-trans"><p>Kura Oncology（纳斯达克代码：KURA - 获取免费报告）在 Zacks Research 发布的一份报告中被升级，从 “强烈卖出” 评级提升至 “持有” 评级，报告于周三发布，Zacks.com 报道。</p>
</div><ul>
<li>Is Kintara Therapeutics A Hidden Gem?</li>
</ul>
<div class="lb-trans"><ul>
<li>Kintara Therapeutics 是隐藏的宝石吗？</li>
</ul>
</div><p>KURA has been the subject of a number of other research reports. Wedbush reiterated an &#34;outperform&#34; rating and set a $36.00 price objective on shares of Kura Oncology in a report on Monday, October 20th. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $40.00 target price on shares of Kura Oncology in a research report on Monday, October 20th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Kura Oncology in a research note on Wednesday, October 8th. Guggenheim began coverage on Kura Oncology in a research report on Thursday, September 4th. They set a &#34;neutral&#34; rating on the stock. Finally, JMP Securities reiterated a &#34;market outperform&#34; rating and set a $24.00 price objective on shares of Kura Oncology in a research note on Monday, October 20th. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Kura Oncology has an average rating of &#34;Moderate Buy&#34; and an average target price of $24.67.</p>
<div class="lb-trans"><p>KURA 还受到其他多份研究报告的关注。Wedbush 在 10 月 20 日的报告中重申了 “跑赢大盘” 评级，并设定了 Kura Oncology 股票的目标价为 36.00 美元。HC Wainwright 在 10 月 20 日的研究报告中重申了 “买入” 评级，并设定了 Kura Oncology 股票的目标价为 40.00 美元。Weiss Ratings 在 10 月 8 日的研究报告中重申了 Kura Oncology 股票的 “卖出（d-）” 评级。Guggenheim 在 9 月 4 日的研究报告中开始覆盖 Kura Oncology，并对该股票设定了 “中性” 评级。最后，JMP Securities 在 10 月 20 日的研究报告中重申了 “市场跑赢大盘” 评级，并设定了 Kura Oncology 股票的目标价为 24.00 美元。十位投资分析师对该股票给予了买入评级，四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Kura Oncology 的平均评级为 “适度买入”，平均目标价为 24.67 美元。</p>
</div><p>Get <strong>Kura Oncology</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Kura Oncology</strong> 的提醒：</p>
</div><p><strong>View Our Latest Stock Report on Kura Oncology</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Kura Oncology 的最新股票报告</strong></p>
</div><h2>Kura Oncology Price Performance</h2>
<div class="lb-trans"><h2>Kura Oncology 价格表现</h2>
</div><p>KURA opened at $10.16 on Wednesday. The business has a fifty day moving average of $9.17 and a 200 day moving average of $7.30. The stock has a market cap of $884.12 million, a P/E ratio of -4.10 and a beta of 0.35. The company has a quick ratio of 6.16, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $19.73.</p>
<div class="lb-trans"><p>KURA 在周三开盘价为 10.16 美元。该公司的 50 日移动平均价为 9.17 美元，200 日移动平均价为 7.30 美元。该股票的市值为 8.8412 亿美元，市盈率为-4.10，贝塔值为 0.35。公司快速比率为 6.16，流动比率为 5.12，债务与股本比率为 0.02。Kura Oncology 的 52 周低点为 5.41 美元，52 周高点为 19.73 美元。</p>
</div><p>Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.28). The business had revenue of $20.75 million during the quarter, compared to analysts' expectations of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. As a group, sell-side analysts anticipate that Kura Oncology will post -2.44 EPS for the current year.</p>
<div class="lb-trans"><p>Kura Oncology（纳斯达克代码：KURA - 获取免费报告）最近于 11 月 4 日发布了其财报。该公司报告季度每股收益为（0.85 美元），低于分析师一致预期的（0.57 美元）0.28 美元。该季度的营业收入为 2075 万美元，而分析师预期为 1748 万美元。Kura Oncology 的股本回报率为-65.42%，净利润率为-208.48%。整体来看，卖方分析师预计 Kura Oncology 在当前年度将发布-2.44 的每股收益。</p>
</div><h2>Insider Buying and Selling at Kura Oncology</h2>
<div class="lb-trans"><h2>Kura Oncology 的内部买卖</h2>
</div><p>In related news, insider Brian T. Powl sold 8,891 shares of the company's stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $79,485.54. Following the transaction, the insider directly owned 99,676 shares of the company's stock, valued at $891,103.44. This represents a 8.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Teresa Brophy Bair sold 8,805 shares of the stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $8.94, for a total value of $78,716.70. Following the completion of the sale, the insider owned 148,043 shares of the company's stock, valued at approximately $1,323,504.42. This trade represents a 5.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 78,058 shares of company stock valued at $697,839. Corporate insiders own 6.40% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Brian T. Powl 于 9 月 29 日星期一出售了 8891 股公司的股票。该股票以平均价格 8.94 美元出售，总交易额为 79485.54 美元。交易后，该内部人士直接持有公司股票 99676 股，价值 891103.44 美元。这代表其持股比例下降了 8.19%。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，内部人士 Teresa Brophy Bair 于 9 月 29 日星期一出售了 8805 股股票。该股票以平均价格 8.94 美元出售，总价值为 78716.70 美元。交易完成后，该内部人士持有公司股票 148043 股，价值约 1323504.42 美元。此交易代表其持股比例下降了 5.61%。该交易的 SEC 文件提供了更多信息。在过去 90 天内，内部人士出售了 78058 股公司股票，价值为 697839 美元。公司内部人士持有公司股票的 6.40%。</p>
</div><h2>Hedge Funds Weigh In On Kura Oncology</h2>
<div class="lb-trans"><h2>对 Kura Oncology 的对冲基金看法</h2>
</div><p>Several hedge funds have recently modified their holdings of the stock. Cerity Partners LLC acquired a new stake in Kura Oncology in the 1st quarter worth approximately $210,000. CWM LLC raised its holdings in shares of Kura Oncology by 892.8% in the first quarter. CWM LLC now owns 28,353 shares of the company's stock worth $187,000 after buying an additional 25,497 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Kura Oncology by 93.8% in the first quarter. Jennison Associates LLC now owns 138,532 shares of the company's stock worth $914,000 after buying an additional 67,035 shares during the last quarter. 1492 Capital Management LLC lifted its stake in shares of Kura Oncology by 25.4% during the first quarter. 1492 Capital Management LLC now owns 429,746 shares of the company's stock worth $2,836,000 after buying an additional 87,148 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Kura Oncology by 23.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,784 shares of the company's stock worth $216,000 after buying an additional 6,154 shares during the period.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对该股票的持有。Cerity Partners LLC 在第一季度收购了 Kura Oncology 的新股份，价值约 210,000 美元。CWM LLC 在第一季度将其在 Kura Oncology 的持股增加了 892.8%。CWM LLC 现在拥有 28353 股公司股票，价值 187,000 美元，此前在上个季度购买了 25497 股。Jennison Associates LLC 在第一季度将其在 Kura Oncology 的持股增加了 93.8%。Jennison Associates LLC 现在拥有 138532 股公司股票，价值 914,000 美元，此前在上个季度购买了 67035 股。1492 Capital Management LLC 在第一季度将其在 Kura Oncology 的持股增加了 25.4%。1492 Capital Management LLC 现在拥有 429746 股公司股票，价值 2836000 美元，此前在此期间购买了 87148 股。最后，Zurcher Kantonalbank Zurich Cantonalbank 在第一季度将其在 Kura Oncology 的持股增加了 23.1%。Zurcher Kantonalbank Zurich Cantonalbank 现在拥有 32784 股公司股票，价值 216,000 美元，此前在此期间购买了 6154 股。</p>
</div><h2>Kura Oncology Company Profile</h2>
<div class="lb-trans"><h2>Kura Oncology 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.</p>
<div class="lb-trans"><p>Kura Oncology, Inc 是一家临床阶段的生物制药公司，开发用于癌症治疗的药物。该公司的产品管线包括针对癌症的小分子候选药物。其主要产品候选药物包括 ziftomenib，一种口服生物可用的小分子抑制剂，针对 menin-KMT2A 相互作用，用于治疗包括急性髓性白血病和急性淋巴细胞白血病在内的基因定义亚型的急性白血病；tipifarnib，一种口服生物可用的法尼基转移酶抑制剂，结合 alpelisib 用于 PIK3CA 依赖的头颈鳞状细胞癌患者；以及 KO-2806，一种法尼基转移酶抑制剂，用于治疗实体瘤。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Kura Oncology</li>
<li>Investing in Travel Stocks Benefits</li>
<li>CAVA Stock Looking for Direction After Earnings Miss</li>
<li>Utilities Stocks Explained – How and Why to Invest in Utilities</li>
<li>3 Small AI Stocks Ready to Explode (All Under $20)</li>
<li>Best Aerospace Stocks Investing</li>
<li>After 16% Fall, Analysts Eye a Big Recovery in Meta Platforms</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Kura Oncology 更好</li>
<li>投资旅游股票的好处</li>
<li>CAVA 股票在财报失利后寻找方向</li>
<li>公用事业股票解析 – 如何以及为何投资公用事业</li>
<li>3 只准备爆发的小型 AI 股票（均低于 20 美元）</li>
<li>最佳航空航天股票投资</li>
<li>在下跌 16% 后，分析师关注 Meta Platforms 的大幅反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1VSQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=KURA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Kura Oncology Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Kura Oncology 吗？</h2>
</div><p>Before you consider Kura Oncology, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Kura Oncology 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kura Oncology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Kura Oncology 并不在名单上。</p>
</div><p>While Kura Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kura Oncology 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kura Oncology（纳斯达克代码：KURA）在 Zacks Research 的评级被上调